The use of more than one inotrope in acute heart failure is associated with increased mortality: a multi-centre observational study

Acute Card Care. 2008;10(4):209-13. doi: 10.1080/17482940802262376.

Abstract

Background: Although weakly supported by scientific evidence, according to guidelines the use of inotropes in acute heart failure is indicated in the presence of hypoperfusion refractory to fluid resuscitation.

Aims: We examined the characteristics of the inotrope-treated patients, as well as, their in-hospital mortality. The frequency and dosing of inotropic infusions in patients admitted with acute heart failure was assessed in detail.

Methods: We included 620 consecutive patients with acute heart failure who were admitted to hospital during three months during spring 2004 in an observational multi-centre study.

Results: Of the patients 84 (14%) were treated with inotropes. Dopamine was used in 46 (7%), dobutamine 22 (4%), epinephrine 5 (1%), norepinephrine in 33 (5%), and levosimendan in 44 (7%) cases. The in-hospital mortality was 21% in the inotrope-treated group, and 5% in the control group. The mortality was 7% if only one inotrope was used. The mortality increased in proportion to the number of inotropes used. Lower blood pressure at admission, low ejection fraction, elevated C-reactive protein and cardiac markers correlated with the inotrope administration.

Conclusion: Inotrope administration is a marker of increased mortality in patients with acute heart failure. Still, the use of a single inotrope during hospital stay seems rather safe.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Aged
  • Aged, 80 and over
  • Cardiotonic Agents / administration & dosage
  • Cardiotonic Agents / therapeutic use*
  • Catecholamines / administration & dosage
  • Catecholamines / therapeutic use*
  • Female
  • Finland / epidemiology
  • Heart Failure / drug therapy*
  • Heart Failure / mortality
  • Hospital Mortality
  • Humans
  • Hydrazones / administration & dosage
  • Hydrazones / adverse effects
  • Hydrazones / therapeutic use
  • Length of Stay
  • Male
  • Middle Aged
  • Pyridazines / administration & dosage
  • Pyridazines / adverse effects
  • Pyridazines / therapeutic use
  • Retrospective Studies
  • Risk Factors
  • Simendan
  • Statistics, Nonparametric
  • Treatment Outcome

Substances

  • Cardiotonic Agents
  • Catecholamines
  • Hydrazones
  • Pyridazines
  • Simendan